Literature DB >> 15515168

Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA.

Katsuhiro Mori1, Reiko Kuni-Kamochi, Naoko Yamane-Ohnuki, Masako Wakitani, Kazuya Yamano, Harue Imai, Yutaka Kanda, Rinpei Niwa, Shigeru Iida, Kazuhisa Uchida, Kenya Shitara, Mitsuo Satoh.   

Abstract

We explored the possibility of converting established antibody-producing cells to cells producing high antibody-dependent cellular cytotoxicity (ADCC) antibodies. The conversion was made by constitutive expression of small interfering RNA (siRNA) against alpha1,6 fucosyltransferase (FUT8). We found two effective siRNAs, which reduce FUT8 mRNA expression to 20% when introduced into Chinese hamster ovary (CHO)/DG44 cells. Selection for Lens culinaris agglutinin (LCA)-resistant clones after introduction of the FUT8 siRNA expression plasmids yields clones producing highly defucosylated (approximately 60%) antibody with over 100-fold higher ADCC compared to antibody produced by the parental cells (approximately 10% defucosylated). Moreover, the selected clones remain stable, producing defucosylated antibody even in serum-free fed-batch culture. Our results demonstrate that constitutive FUT8 siRNA expression can control the oligosaccharide structure of recombinant antibody produced by CHO cells to yield antibodies with dramatically enhanced ADCC. 2004 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15515168     DOI: 10.1002/bit.20326

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  39 in total

1.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 2.  Cell culture processes for monoclonal antibody production.

Authors:  Feng Li; Natarajan Vijayasankaran; Amy Yijuan Shen; Robert Kiss; Ashraf Amanullah
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

3.  Using cell engineering and omic tools for the improvement of cell culture processes.

Authors:  Darrin Kuystermans; Britta Krampe; Halina Swiderek; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2007-02-24       Impact factor: 2.058

Review 4.  Production of therapeutic antibodies with controlled fucosylation.

Authors:  Naoko Yamane-Ohnuki; Mitsuo Satoh
Journal:  MAbs       Date:  2009-05-28       Impact factor: 5.857

Review 5.  Advancement in bioprocess technology: parallels between microbial natural products and cell culture biologics.

Authors:  Arpan A Bandyopadhyay; Anurag Khetan; Li-Hong Malmberg; Weichang Zhou; Wei-Shou Hu
Journal:  J Ind Microbiol Biotechnol       Date:  2017-02-09       Impact factor: 3.346

6.  Glycoengineering of Mammalian Expression Systems on a Cellular Level.

Authors:  Kelley M Heffner; Qiong Wang; Deniz Baycin Hizal; Özge Can; Michael J Betenbaugh
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

7.  Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.

Authors:  Solomon Z Okbazghi; Apurva S More; Derek R White; Shaofeng Duan; Ishan S Shah; Sangeeta B Joshi; C Russell Middaugh; David B Volkin; Thomas J Tolbert
Journal:  J Pharm Sci       Date:  2016-01-09       Impact factor: 3.534

8.  Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity.

Authors:  Yoshinobu Konno; Yuki Kobayashi; Ken Takahashi; Eiji Takahashi; Shinji Sakae; Masako Wakitani; Kazuya Yamano; Toshiyuki Suzawa; Keiichi Yano; Toshio Ohta; Masamichi Koike; Kaori Wakamatsu; Shinji Hosoi
Journal:  Cytotechnology       Date:  2011-08-27       Impact factor: 2.058

Review 9.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

10.  Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.

Authors:  Akito Natsume; Rinpei Niwa; Mitsuo Satoh
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.